Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

Mayer D, Shukla A, Enzmann H (2008) Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 114:38–44

Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2009) Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25:41–49

Rosén M (2002) National Health Data Registers: a Nordic heritage to public health. Scand J Public Health 30:81–85

Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. doi: 10.1007/s00125-009-1418-4

Steineck G, Hunt H, Adolfsson J (2006) A hierarchical step-model for causation of bias-evaluating cancer treatment with epidemiological methods. Acta Oncol 45:421–429

Socialstyrelsen (The National Board of Health and Welfare, Sweden) (2008) Patientregistret. Available from www.socialstyrelsen.se/Statistik/statistik_amne/sluten_vard/Patientregistret.htm , accessed 18 June 2009

Ericson A, Eriksson M, Källén B, Westerholm P, Zetterström R (1984) Delivery outcome of women working in laboratories during pregnancy. Arch Environ Health 39:5–10

Statistics Sweden (2004) The Swedish Register of Education. Available from www.scb.se/statistik/UF/UF0506/Produktbeskrivning_short_English_UF0506_20040101r.doc , accessed 18 June 2009

Socialstyrelsen (The National Board of Health and Welfare, Sweden) (2003) Causes of Death Register. Available from www.socialstyrelsen.se/en/Statistics/statsbysubject/The_Cause_of_Death_Register.htm , accessed 18 June 2009

Wettermark B, Hammar N, Fored CM et al (2007) The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16:726–735

Socialstyrelsen (The National Board of Health and Welfare, Sweden) (2008) Cancer Incidence in Sweden 2007. Available from www.socialstyrelsen.se/Publicerat/2008/10204/2008-125-16.htm , accessed 18 June 2009

Mattsson B, Wallgren A (1984) Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 23:305–313

Barlow L, Westergren K, Holmberg L, Talbäck M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48:27–33

Gudbjörnsdòttir S, Cederholm J, Nilsson PM, Eliasson B (2003) The National Diabetes Register in Sweden: an implementation of the St. Vincent declaration for quality improvement in diabetes care. Diabetes Care 26:1270–1276

Trichopoulos D, Hsieh CC, MacMahon B et al (1983) Age at any birth and breast cancer risk. Int J Cancer 31:701–704

Rapp K, Schroeder J, Klenk J et al (2005) Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 93:1062–1067

Campbell RT, Li X, Dolecek TA, Barrett RE, Weaver KE, Warnecke RB (2009) Economic, racial and ethnic disparities in breast cancer in the US: towards a more comprehensive model. Health Place 15:855–864

Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350:1047–1059

Ellison RC, Zhang Y, McLennan CE, Rothman KJ (2001) Exploring the relation of alcohol consumption to risk of breast cancer. Am J Epidemiol 154:740–747

Levi F, Pasche C, Lucchini F, La Vecchia C (1996) Alcohol and breast cancer in the Swiss Canton of Vaud. Eur J Cancer 32A:2108–2113

Adami H-O, Hunter D, Trichopoulos D (2002) Textbook of cancer epidemiology. Oxford University Press, Oxford

Easton DF, Narod SA, Ford D, Steel M (1994) The genetic epidemiology of BRCA1. Breast cancer linkage consortium. Lancet 344:761

Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343:692–695

Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71

Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792

Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62:676–689

Rothman KJ, Greenland S (1998) Modern epidemiology. Lippincott Williams & Wilkins, Philadelphia

Cohen SM, Shirai T, Steineck G (2000) Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl (205):105–115

Thiede T, Christensen BC (1969) Bladder tumours induced by chlornaphazine. A five-year follow-up study of chlornaphazine-treated patients with polycythaemia. Acta Med Scand 185:133–137

Giovannucci E, Pollak MN, Platz EA et al (2000) A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9:345–349

Kaaks R, Lukanova A (2001) Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60:91–106

Nam RK, Trachtenberg J, Jewett MA et al (2005) Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 14:1270–1273